The VEXAS-MDS Interface: Integrating Morphological Markers and Clonal Evolution to Predict Response to Targeted Myeloid Cell Therapies (SOHO 2026) - Sep 1, 2026 - Abstract #MDS-540; Location: LEVEL 3, HALL B3; "The VEXAS-MDS interface necessitates a shift from nonspecific immunosuppression to a clone-directed paradigm. Integrating morphological markers with quantitative UBA1 clonal kinetics is essential for predicting therapeutic failure and identifying the best course for curative intervention. Although ruxolitinib and HMAs offer effective symptomatic and clonal suppression, their administration requires vigilant monitoring for life-threatening infectious complications."
Hematological Malignancies • Myelodysplastic Syndrome • Oncology • DNMT3A • TET2
|